

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Carl Arne Krister Borrebaeck and Roland Carlson

Serial No.: 09/811,075

Art Unit: Not Yet Assigned

Filed: March 16, 2001

Examiner: Not Yet Assigned



METHODS OF MAKING AND USING MICROARRAYS OF BIOLOGICAL MATERIALS

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including six (6) pages of Form PTO-1449 and a copy of each document cited therein.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
5,856,090	01-05-1999	Epstein	435/6
5,955,281	09-21-1999	Brann	435/6
5,969,108	10-19-1999	McCafferty et al.	530/387.3

04 CO
08/13/01
LB
10/15/01

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 95/35505 A1	12-28-1995	The Board of Trustees of the Leland Stanford Junior University	PCT
WO 98/37186 A1	08-27-1998	Actinova Limited	PCT
WO 99/24823 A1	05-20-1999	Protiveris, Inc.	PCT
WO 99/31267 A1	06-24-1999	Sepracor, Inc.	PCT
WO 99/36081 A1	07-22-1999	UAB Research Foundation	PCT
WO 99/39210 A1	08-07-1999	Samuel Miller	PCT
WO 99/40434 A1	08-12-1999	Invitrogen	PCT
WO 99/51773 A1	10-14-1999	Phylos, Inc.	PCT
WO 00/09464 A1	02-24-2000	Phylos, Inc.	PCT
WO 00/35473 A1	06-22-2000	Scios, Inc.	PCT
WO 00/49417 A1	08-24-2000	Arcaris, Inc.	PCT
WO 00/53812 A1	09-14-2000	President and Fellows of Harvard College	PCT

Publications

AHLUWALIA, et al., "A comparative study of protein immobilization techniques for optical immunosensors," *Biosens. Bioelectron.* 7(3):207-214 (1992).

AULAK, et al., "Post-transcriptional regulation of the arginine transporter Cat-1 by amino acid availability," *J Biol Chem* 274(43):30424-32 (1999).

BARBAS, et al., "Assembly of combinatorial antibody libraries on phage surfaces: the gene III site," *Proc Natl Acad Sci USA* 88:7978-7982 (1991)

BHATIA, et al., "Use of thiol-terminal silanes and heterobifunctional crosslinkers for immobilization of antibodies on silica surfaces," *Anal. Biochem* 178(2):408-413 (1989).

BORREBAECK, "Antibodies in diagnostics – from immunoassays to protein chips," *Immunol. Today* 21:379-382 (2000).

CHARRIERE-BERTRAND & NUNEZ, "Regulation of tubulin, tau and microtubule associated protein 2 expression during mouse brain development," *J Neurochem Int* 21(4):535-41 (1992).

CLACKSON, et al., "Making antibody fragments using phage display libraries," *Nature* 352:624-628 (1991).

DAUGHERTY, et al., "Antibody affinity maturation using bacterial surface display," *Protein Eng* 11(9):825-32 (1998).

DAUGHERTY, et al., "Development of an optimized expression system for the screening of antibody libraries displayed on the *E. coli* surface," *Protein Eng* 12(7):613-21 (1999).

DAVIES, et al., "Profiling of amyloid β peptide variants using SELDI ProteinChip arrays," *Biotechniques* 27(6):1258-61 (1999).

DE HAARD, et al., "A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies," *J Biol Chem* 274:18218-18230 (1999).

DE SAIZIEU, et al., "Bacterial transcript imaging by hybridization of total RNA to oligonucleotide arrays," *Nat Biotechnol* 16(1):45-8 (1998).

EKSTROM, et al., "Integrated microanalytical technology enabling rapid and automated protein identification," *Anal Chem* 72(2):286-93 (2000).

ENGBERG, et al., "Phage-display libraries of murine and human antibody Fab fragments," *Mol Biotechnol* 6(3):287-310 (1996).

FREIJ-LARSSON, et al., "Adsorption behaviour of amphiphilic polymers at hydrophobic surfaces: effects on protein adsorption," *Biomaterials* 17(22):2199-2207 (1996).

GÖRG, et al., "Improved horizontal two-dimensional electrophoresis with hybrid isoelectric focusing in immobilized pH gradients in the first dimension and laying-on transfer to the second dimension," *Electrophoresis* 6:599-604 (1985).

GRIFFITHS, et al. "Isolation of high affinity human antibodies directly from large synthetic repertoires," *EMBO J* 13:3245-3260 (1994).

GUNNERIUSSEN, et al., "Staphylococcal surface display of immunoglobulin A (IgA)- and IgE-specific in vitro-selected binding proteins (Affibodies) based on *Staphylococcus aureus* protein A," *Appl Environ Microbiol* 65(9):4134-40 (1999).

HANES & PLUCKTHUN, "In vitro selection and evolution of functional proteins by using ribosome display," *Proc Natl Acad Sci USA* 94(10):4937-42 (1997).

HE & TAUSSIG, "Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for *in vitro* display and evolution of antibody combining sites," *Nucleic Acids Res* 25(24):5132-4 (1997).

HOOGENBOOM & WINTER, "By-passing immunisation," *J. Mol Bio* 227:381-388 (1992).

JENSEN, et al., "Peptide sequencing of 2-DE gel-isolated proteins by nanoelectrospray tandem mass spectrometry," *Methods Mol Biol* 112:571-88 (1999).

JIRHOLT, et al., "Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework," *Gene* 215:471-476 (1998).

JORGENSEN & LUKACS, "Capillary zone electrophoresis," *Science* 222(4621):266-72 (1983).

KENAN & KEENE, "In vitro selection of aptamers from RNA libraries," *Methods Mol Biol* 118:217-31 (1999).

KIEKE, et al., "Selection of functional T cell receptor mutants from a yeast surface-display library," *Proc Natl Acad Sci USA* 96(10):5651-6 (1999).

KLINGENSPOR, et al., "Multiple regulatory steps are involved in the control of lipoprotein lipase activity in brown adipose tissue," *J Lipid Res* 37(8):1685-95 (1996).

LOCKHART, et al., "Expression monitoring by hybridization to high-density oligonucleotide arrays," *Nat Biotechnol* 14(13):1675-80 (1996).

MALMQVIST, "BIACORE: an affinity biosensor system for characterization of biomolecular interactions," *Biochem Soc Trans* 27(2):335-40 (1999).

MARKS, et al., "By-passing immunization," *J Mol Biol* 222(3):581-97 (1991).

MARSHALL & HODGSON, "DNA chips: an array of possibilities," *Nat. Biotech.* 16:27-31 (1998).

MCCAFFERTY & JOHNSON, "Construction and screening of antibody display libraries," I in *Phage Display of Peptides and Proteins: a Laboratory Manual*. (Eds. Kay, BK., Winter, J., and McCafferty, J.) Academic Press, San Diego, CA (1996) pp. 79.

NEMOTO, et al., "In vitro virus: Bonding of mRNA bearing puromycin at the 3'-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro," *FEBS Lett* 414(2):405-8 (1997).

O'FARRELL, "High resolution two-dimensional electrophoresis of proteins," *J.Biol.Chem.* 250:4007-4021 (1975).

PEASE, et al., "Light-generated oligonucleotide arrays for rapid DNA sequence analysis," *PNAS* 91(11):5022-5026 (1994).

PERROT, et al., "Two dimensional gel protein database of *Saccharomyces cerevisiae* (update 1995)," *Electrophoresis* 20(11):2280-98 (1999).

PORATH & FLODIN, "Gel filtration: a method for desalting and group separationm," *Nature* 193:1657-1659 (1959).

REYMOND, et al., "Standardized characterization of gene expression in human colorectal epithelium by two-dimensional electrophoresis," *Electrophoresis* 18(15):2842-8 (1997).

SANTI, et al., "Bacteriophage lambda display of complex cDNA libraries: a new approach to functional genomics," *J Mol Biol* 296(2):497-508 (2000).

SHEETS, et al., "Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens," *Proc Natl Acad Sci USA* 26:6157-6162 (1998).

SHUSTA, et al., "Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency," *J Mol Biol* 292(5):949-56 (1999).

SMITH, "Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface," *Science* 228(4705):1315-7 (1985).

TOWBIN, "Immunoblotting in the clinical laboratory," *J Clin Chem Clin Biochem* 27(8):495-501 (1989).

VAUGHAN, et al., "Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library," *Nat Biotechnol* 14:309-314 (1996).

WINTER, "Bacteriophage display: peptide libraries and drug discovery," *Drug Dev. Res.* 33:71-89 (1994).

WODICKA, et al., "Genome-wide expression monitoring in *Saccharomyces cerevisiae*," *Nat Biotchnol* 15(13):1359-67 (1997).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

A handwritten signature in black ink, appearing to be 'P. L. Pabst', written over a horizontal line.

Patrea L. Pabst
Reg. No. 31,284

Dated: August 29, 2001


HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8500
FAX 404-817-0470
www.hklaw.com

U.S.S.N.: 09/811,075
Filed: March 16, 2001
INFORMATION DISCLOSURE STATEMENT

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: August 29, 2001


Kimberly L. Adams

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/811,075
		Filing Date	March 16, 2001
		First Named Inventor	Carl Arne Krister Borrebaeck
		Group Art Unit	
		Examiner Name	
Sheet 1 of 6		Attorney Docket Number	BIOT 100

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		5,856,090		Epstein	01-05-1999	
		5,955,281		Brann	09-21-1999	
		5,969,108		McCafferty et al.	10-19-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
		WO	95/35505	A1	The Board of Trustees of the Leland Stanford Junior University	12-28-1995		
		WO	98/37186	A1	Actinova Limited	08-27-1998		
		WO	99/24823	A1	Protiveris, Inc.	05-20-1999		
		WO	99/31267	A1	Sepracor, Inc.	06-24-1999		
		WO	99/36081	A1	UAB Research Foundation	07-22-1999		
		WO	99/39210	A1	Samuel Miller	08-07-1999		
		WO	99/40434	A1	Invitrogen	08-12-1999		
		WO	99/51773	A1	Phylos, Inc.	10-14-1999		
		WO	00/09464	A1	Phylos, Inc.	02-24-2000		
		WO	00/35473	A1	Scios, Inc.	06-22-2000		
		WO	00/49417	A1	Arcaris, Inc.	08-24-2000		
		WO	00/53812	A1	President and Fellows of Harvard College	09-14-2000		

Examine Signature	Date Considered
-------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/811,075
		Filing Date	March 16, 2001
		First Named Inventor	Carl Arne Krister Borrebaeck
		Group Art Unit	
		Examiner Name	
Sheet 2 of 6		Attorney Docket Number	BIOT 100

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		AHLUWALIA, et al., "A comparative study of protein immobilization techniques for optical immunosensors," <i>Biosens. Bioelectron.</i> 7(3):207-214 (1992).	
		AULAK, et al., "Post-transcriptional regulation of the arginine transporter Cat-1 by amino acid availability," <i>J Biol Chem</i> 274(43):30424-32 (1999).	
		BARBAS, et al., "Assembly of combinatorial antibody libraries on phage surfaces: the gene III site," <i>Proc Natl Acad Sci USA</i> 88:7978-7982 (1991)	
		BHATIA, et al., "Use of thiol-terminal silanes and heterobifunctional crosslinkers for immobilization of antibodies on silica surfaces," <i>Anal. Biochem</i> 178(2):408-413 (1989).	
		BORREBAECK, "Antibodies in diagnostics – from immunoassays to protein chips," <i>Immunol. Today</i> 21:379-382 (2000).	
		CHARRIERE-BERTRAND & NUNEZ, "Regulation of tubulin, tau and microtubule associated protein 2 expression during mouse brain development," <i>J Neurochem Int</i> 21(4):535-41 (1992).	
		CLACKSON, et al., "Making antibody fragments using phage display libraries," <i>Nature</i> 352:624-628 (1991).	
		DAUGHERTY, et al., "Antibody affinity maturation using bacterial surface display," <i>Protein Eng</i> 11(9):825-32 (1998).	
		DAUGHERTY, et al., "Development of an optimized expression system for the screening of antibody libraries displayed on the <i>E. coli</i> surface," <i>Protein Eng</i> 12(7):613-21 (1999).	
		DAVIES, et al., "Profiling of amyloid β peptide variants using SELDI ProteinChip arrays," <i>Biotechniques</i> 27(6):1258-61 (1999).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


+

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/811,075
		Filing Date	March 16, 2001
		First Named Inventor	Carl Arne Krister Borrebaeck
		Group Art Unit	
		Examiner Name	
Sheet 3 of 6		Attorney Docket Number	BIOT 100



OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		DE HAARD, et al., "A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies," <i>J Biol Chem</i> 274:18218-18230 (1999).	
		DE SAIZIEU, et al., "Bacterial transcript imaging by hybridization of total RNA to oligonucleotide arrays," <i>Nat Biotechnol</i> 16(1):45-8 (1998).	
		EKSTROM, et al., "Integrated microanalytical technology enabling rapid and automated protein identification," <i>Anal Chem</i> 72(2):286-93 (2000).	
		ENGBERG, et al., "Phage-display libraries of murine and human antibody Fab fragments," <i>Mol Biotechnol</i> 6(3):287-310 (1996).	
		FREIJ-LARSSON, et al., "Adsorption behaviour of amphiphilic polymers at hydrophobic surfaces: effects on protein adsorption," <i>Biomaterials</i> 17(22):2199-2207 (1996).	
		GÖRG, et al., "Improved horizontal two-dimensional electrophoresis with hybrid isoelectric focusing in immobilized pH gradients in the first dimension and laying-on transfer to the second dimension," <i>Electrophoresis</i> 6:599-604 (1985).	
		GRIFFITHS, et al. "Isolation of high affinity human antibodies directly from large synthetic repertoires," <i>EMBO J</i> 13:3245-3260 (1994).	
		GUNNERIUSSON, et al., "Staphylococcal surface display of immunoglobulin A (IgA)- and IgE-specific in vitro-selected binding proteins (Affibodies) based on <i>Staphylococcus aureus</i> protein A," <i>Appl Environ Microbiol</i> 65(9):4134-40 (1999).	
		HANES & PLUCKTHUN, "In vitro selection and evolution of functional proteins by using ribosome display," <i>Proc Natl Acad Sci USA</i> 94(10):4937-42 (1997).	
		HE & TAUSSIG, "Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites," <i>Nucleic Acids Res</i> 25(24):5132-4 (1997).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/811,075
		Filing Date	March 16, 2001
		First Named Inventor	Carl Arne Krister Borrebaeck
		Group Art Unit	
		Examiner Name	
Sheet 4	6	Attorney Docket Number	BIOT 100



OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		HOOGENBOOM & WINTER, "By-passing immunisation," <i>J. Mol Biol</i> 227:381-388 (1992).	
		JENSEN, et al., "Peptide sequencing of 2-DE gel-isolated proteins by nanoelectrospray tandem mass spectrometry," <i>Methods Mol Biol</i> 112:571-88 (1999).	
		JIRHOLT, et al., "Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework," <i>Gene</i> 215:471-476 (1998).	
		JORGENSEN & LUKACS, "Capillary zone electrophoresis," <i>Science</i> 222(4621):266-72 (1983).	
		KENAN & KEENE, "In vitro selection of aptamers from RNA libraries," <i>Methods Mol Biol</i> 118:217-31 (1999).	
		KIEKE, et al., "Selection of functional T cell receptor mutants from a yeast surface-display library," <i>Proc Natl Acad Sci USA</i> 96(10):5651-6 (1999).	
		KLINGENSPOR, et al., "Multiple regulatory steps are involved in the control of lipoprotein lipase activity in brown adipose tissue," <i>J Lipid Res</i> 37(8):1685-95 (1996).	
		LOCKHART, et al., "Expression monitoring by hybridization to high-density oligonucleotide arrays," <i>Nat Biotechnol</i> 14(13):1675-80 (1996).	
		MALMQVIST, "BIACORE: an affinity biosensor system for characterization of biomolecular interactions," <i>Biochem Soc Trans</i> 27(2):335-40 (1999).	
		MARKS, et al., "By-passing immunization," <i>J Mol Biol</i> 222(3):581-97 (1991).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Application Number	09/811,075
		Filing Date	March 16, 2001
		First Named Inventor	Carl Arne Krister Borrebaeck
		Group Art Unit	
		Examiner Name	
Sheet	6	Attorney Docket Number	BIOT 100

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		MARSHALL & HODGSON, "DNA chips: an array of possibilities," <i>Nat. Biotech.</i> 16:27-31 (1998).	
		MCCAFFERTY & JOHNSON, "Construction and screening of antibody display libraries," I in <i>Phage Display of Peptides and Proteins: a Laboratory Manual</i> . (Eds. Kay, BK., Winter, J., and McCafferty, J.) Academic Press, San Diego, CA (1996) pp. 79.	
		NEMOTO, et al., "In vitro virus: Bonding of mRNA bearing puromycin at the 3'-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro," <i>FEBS Lett</i> 414(2):405-8 (1997).	
		O'FARRELL, "High resolution two-dimensional electrophoresis of proteins," <i>J.Biol.Chem.</i> 250:4007-4021 (1975).	
		PEASE, et al., "Light-generated oligonucleotide arrays for rapid DNA sequence analysis," <i>PNAS</i> 91(11):5022-5026 (1994).	
		PERROT, et al., "Two dimensional gel protein database of <i>Saccharomyces cerevisiae</i> (update 1995)," <i>Electrophoresis</i> 20(11):2280-98 (1999).	
		PORATH & FLODIN, "Gel filtration: a method for desalting and group separationm," <i>Nature</i> 193:1657-1659 (1959).	
		REYMOND, et al., "Standardized characterization of gene expression in human colorectal epithelium by two-dimensional electrophoresis," <i>Electrophoresis</i> 18(15):2842-8 (1997).	
		SANTI, et al., "Bacteriophage lambda display of complex cDNA libraries: a new approach to functional genomics," <i>J Mol Biol</i> 296(2):497-508 (2000).	
		SHEETS, et al., "Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens," <i>Proc Natl Acad Sci USA</i> 26:6157-6162 (1998).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/811,075
		Filing Date	March 16, 2001
		First Named Inventor	Carl Arne Krister Borrebaeck
		Group Art Unit	
		Examiner Name	
Sheet 6 of 6	Attorney Docket Number	BIOT 100	



OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SHUSTA, et al., "Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency," <i>J Mol Biol</i> 292(5):949-56 (1999).	
		SMITH, "Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface," <i>Science</i> 228(4705):1315-7 (1985).	
		TOWBIN, "Immunoblotting in the clinical laboratory," <i>J Clin Chem Clin Biochem</i> 27(8):495-501 (1989).	
		VAUGHAN, et al., "Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library," <i>Nat Biotechnol</i> 14:309-314 (1996).	
		WINTER, "Bacteriophage display: peptide libraries and drug discovery," <i>Drug Dev. Res.</i> 33:71-89 (1994).	
		WODICKA, et al., "Genome-wide expression monitoring in <i>Saccharomyces cerevisiae</i> ," <i>Nat Biotechnol</i> 15(13):1359-67 (1997).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.